Genetix Biotherapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Genetix Biotherapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Genetix Biotherapeutics: 12 sponsored US clinical trials, 2 recruiting.
Genetix Biotherapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cerebral Adrenoleukodystrophy (CALD), with 3 trials.
Top-decile sponsor footprint
Genetix Biotherapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
12 total, page 1 of 1
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
NCT06224413
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
NCT06271512
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
NCT04293185
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
NCT02698579
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
NCT02633943
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
NCT03852498
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
NCT03207009
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
NCT02906202
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
NCT02204904
A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease
NCT02140554
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
NCT01896102
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
NCT01745120
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 4 |
What is open in the Genetix Biotherapeutics pipeline
2 recruiting of 12 indexed (17% open); 6 completed (50%).
Phase mix: 4 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Cerebral Adrenoleukodystrophy (CALD) (3 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genetix Biotherapeutics: open-pipeline peers nationwide
Peers matched on 12 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Genetix Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Anthos Therapeutics · 17% recruiting · 6 trials
Related
What to do with this Genetix Biotherapeutics page
12 registered trials is a research-attention snapshot, not an endorsement of Genetix Biotherapeutics or any single study.
- 2 of Genetix Biotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cerebral Adrenoleukodystrophy (CALD) is the condition Genetix Biotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cerebral Adrenoleukodystrophy (CALD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Genetix Biotherapeutics pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.